|
[1]WHO.Hepatitis C fact sheets[EB/OL].[2016-7].http://www.who.int/mediacentre/factsheets/fs164/en/
|
|
[2]CACOUB P, RENOU C, ROSENTHAL E, et al.Extrahepatic manifestations associated with hepatitis C virus infection.A prospective multicenter study of 321 patients.The GERMIVIC.Groupe d'Etude et de Rechercheen Medecine Interne et Maladies Infectieuses sur le Virus de I'Hepatite C[J].Medicine (Baltimore) , 2000, 79 (1) :47-56.
|
|
[3]CACOUB P, POYNARD T, GHILLANI P, et al.Extrahepatic manifestations of chronic hepatitis C.MULTIVIRC Group.Multidepartment Virus C[J].Arthritis Rheum, 1999, 42 (10) :2204-2212.
|
|
[4]GILL K, GHAZINIAN H, MANCH R, et al.Hepatitis C virus as a systemic disease:reaching beyond the liver[J].Hepatol Int, 2016, 10 (3) :415-423.
|
|
[5]SATAPATHY SK, LINGISETTY CS, WILLIAMS S, et al.Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection[J].Hepatol Int, 2012, 6 (1) :369-378.
|
|
[6]BUTT AA, WANG X, FRIED LF.HCV infection and the incidence of CKD[J].Am J Kidney Dis, 2011, 57 (3) :396-402.
|
|
[7]LI WC, LEE YY, CHEN IC, et al.Age and genderdifferences in the relationship between hepat C infection and all stages of chronic kidney disease[J].J Viral Hepat, 2014, 21 (10) :706-715.
|
|
[8]YOUNOSSI Z, PARK H, HENRY L, et al.Extrahepatic manifestations of hepatitis C:a meta-analysis of prevalence, quality of life, and economic burden[J].Gastroenterology, 2016, 150 (7) :1599-1608.
|
|
[9]EL-SERAG HB, HAMPEL H, YEH C, et al.Extrahepatic manifestations of hepatitis C among United States male veterans[J].Hepatology, 2002, 36 (6) :1439-1445.
|
|
[10]FABRIZI F, PLAISIER E, SAADOUN D, et al.Hepatitis C virus infection and kidney disease:a meta-analysis[J].Clin J Am Soc Nephrol, 2012, 7 (4) :549-557.
|
|
[11] CHENG ZJ, ZHOU BT, LIU XQ.Extrahepatic manifestations of chronic hepatitis C:a clinical analysis of 297 cases[C].The 2013Annual Conference on Liver Diseases and Infection in Beijing:49-53. (in Chinese) 程兆晶, 周宝桐, 刘晓清.慢性丙型肝炎肝外表现297例临床分析[C].北京地区肝病、感染学术年会.2013:49-53.
|
|
[12]FABRIZI F, MESSA P, MARTIN P.Novel evidence on hepatitis C virus-associated glomerular disease[J].Kidney Int, 2014, 86 (3) :466-469.
|
|
[13]BARSOUM RS.Hepatitis C virus:from entry to renal injury—facts and potentials[J].Nephrol Dial Transplant, 2007, 22 (7) :1840-1848.
|
|
[14]WORNLE M, SCHMID H, BANAS B, et al.Novel role of tolllike receptor 3 in hepatitis C-associated glomerulonephritis[J].Am J Pathol, 2006, 168 (2) :370-385.
|
|
[15]BANAS MC, BANAS B, HUDKINS KL, et al.TLR4 links podocytes with the innate immune system to mediate glomerular injury[J].J Am Soc Nephrol, 2008, 19 (4) :704-713.
|
|
[16]MORALES JM, MORALES E, ANDRS A, et al.Glomerulonephritis associated with hepatitis C virus infection[J].Curr Opin Nephrol Hypertens, 1999, 8 (2) :205-211.
|
|
[17]OZKOK A, YILDIZ A.Hepatitis C virus associated glomerulopathies[J].World J Gastroenterol, 2014, 20 (24) :7544-7554.
|
|
[18]D'AMICO G.Renal involvement in hepatitis C infection:cryoglobulinemic glomerulonephritis[J].Kidney Int, 1998, 54 (2) :650-671.
|
|
[19]FABRIII F, POZZI C, FARINA M, et al.Hepatitis C virus infection and acute or chronic glomerulonephritis:an epidemiological and clinical appraisal[J].Nephrol Dial Transplant, 1998, 13 (8) :1991-1997.
|
|
[20]TANG SC, LAI KN.Hepatitis C virus-associated glomerulonephritis[J].Contrib Nephrol, 2013, 181:194-206.
|
|
[21]DAVDA R, PETERSON J, WEINER R, et al.Membranous glomerulonephritis in association with hepatitis C virus infection[J].Am J Kidney Dis, 1993, 22 (3) :452-455.
|
|
[22]ROLLINO C, ROCCATELLO D, GIACHINO O, et al.Hepatitis C virus infection and membranous glomerulonephritis[J].Nephron, 1991, 59 (2) :319-320.
|
|
[23]JI F, LI Z, GE H, et al.Successful interferon-alpha treatment in a patient with Ig A nephropathy associated with hepatitis C virus infection[J].Intern Med, 2010, 49 (22) :2531-2532.
|
|
[24]JI FP, LI ZX, TIAN CY, et al.Ig A nephropathy associated with hepatitis C virus infection:a case report[J].Chin J Hepatol, 2010, 18 (9) :718-719. (in Chinese) 纪泛扑, 李政霄, 田长印, 等.丙型肝炎相关性Ig A肾病1例[J].中华肝脏病杂志, 2010, 18 (9) :718-719.
|
|
[25]ALTRAIF IH, ABDULLA AS, ALSEBAYEL MI, et al.Hepatitis C associated glomerulonephritis[J].Am J Nephrol, 1995, 15 (5) :407-410.
|
|
[26]SHAH HH, PATEL C.Long-term response to peginterferon in hepatitis C virus-associated nephrotic syndrome from focal segmental glomerulosclerosis[J].Ren Fail, 2013, 35 (8) :1182-1185.
|
|
[27]FOGO A, QURESHI N, HORN RG.Morphologic and clinical features of fibrillary glomerulonephritis versus immunotactoid glomerulopathy[J].Am J Kidney Dis, 1993, 22 (3) :367-377.
|
|
[28]MARKOWITZ GS, CHENG JT, COLVIN RB, et al.Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy[J].J Am Soc Nephrol, 1998, 9 (12) :2244-2252.
|
|
[29]CORONEOS E, TRUONG L, OLIVERO J.Fibrillary glomerulonephritis associated with hepatitis C viral infection[J].Am J Kidney Dis, 1997, 29 (1) :132-135.
|
|
[30]GUERRA G, NARAYAN G, RENNKE HG, et al.Crescentic fibrillary glomerulonephritis associated with hepatitis C viral infection[J].Clin Nephrol, 2003, 60 (5) :364-368.
|
|
[31]FABRIZI F, PLAISIER E, SAADOUN D, et al.Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease[J].Am J Kidney Dis, 2013, 61 (4) :623-637.
|
|
[32]Kidney Disease:Improving Global Outcomes (KDIGO) .KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease[J].Kidney Int Suppl, 2008, 73 (Suppl 109) :s1-s99.
|
|
[33]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2016[J].J Hepatol, 2017, 66 (1) :153-194.
|
|
[34]ZHANG Y, LENG XJ, SHEN JC, et al.An excerpt of APASL consensus statements and recommendation on treament of hepatitis C[J].J Clin Hepatol, 2016, 32 (7) :1245-1247. (in Chinese) 张莹, 冷雪君, 申姣春, 等.《2016年亚太肝病学会共识建议:丙型肝炎的治疗》摘译[J].临床肝胆病杂志, 2016, 32 (7) :1245-1247.
|
|
[35]OHTA S, YOKOYAMA H, WADA T, et al.Exacerbation of glomerulonephritis in subjects with chronic hepatitis C virus infection after interferon therapy[J].Am J Kidney Dis, 1999, 33 (6) :1040-1048.
|
|
[36]FABRIZI F, MARTIN P, CACOUB P, et al.Treatment of hepatitis C-related kidney disease[J].Expert Opin Pharmacother, 2015, 16 (12) :1815-1827.
|
|
[37]SAADOUN D, THIBAULT V, SI AHMED SN, et al.Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis:VASCUVALDIC study[J].Ann Rheum Dis, 2016, 75 (10) :1777-1782.
|
|
[38]SISE ME, BLOOM AK, WISOCKY J, et al.Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents[J].Hepatology, 2016, 63 (2) :408-417.
|
|
[39]ROTH D, NELSON D, BRUCHFELD A, et al.LP02:C-surfer:grazoprevir plus elbasvir in treatment-na6ve and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease[J].J Hepatol, 2015, 62:s263-s264.
|
|
[40]POCKROS PJ, REDDY KR, MANTRY PS, et al.Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease[J].Gastroenterology, 2016, 150 (7) :1590-1598.
|
|
[41]MAHALE P, KONTOYIANNIS DP, CHEMALY RF, et al.Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients[J].J Hepatol, 2012, 57 (6) :1177-1185.
|
|
[42]SAADOUN D, ROSENZWAJG M, JOLY F, et al.Regulatory Tcell responses to low-dose interleukin-2 in HCV-induced vasculitis[J].N Engl J Med, 2011, 365 (22) :2067-2077.
|
DownLoad: